REAL-LIFE INFLIXIMAB AND ADALIMUMAB TROUGH LEVEL AND ANTI-DRUG ANTIBODY MEASUREMENTS IN RHEUMATOLOGY: THE FINNISH EXPERIENCE

被引：0
|
作者：
Ho, D. [1 ]
Valtanen, S. [2 ]
Havana, M. [2 ]
Kroger, L. [3 ]
Eklund, K. [4 ,5 ]
Jokiranta, S. [1 ,2 ]
机构：
[1] Univ Helsinki, Immunobiol, Res Programs Unit, Helsinki, Finland
[2] United Medix Labs Ltd, Helsinki, Finland
[3] Kuopio Univ Hosp, Pediat Rheumatol, Kuopio, Finland
[4] Univ Helsinki, Rheumatol, Helsinki, Finland
[5] Helsinki Univ Hosp, Helsinki, Finland
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2017年 / 76卷
关键词：
D O I：
10.1136/annrheumdis-2017-eular.5943
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
SAT0152
引用
收藏
页码：827 / 827
页数：1
相关论文
共 36 条
  • [1] Trough levels, drug switching and antidrug antibody loss: Analysis of real-life infliximab and adalimumab data in IBD
    Ho, D.
    Sipponen, T.
    Jokiranta, T. S.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S476 - S476
  • [2] Development of anti-drug monoclonal antibody panels against adalimumab and infliximab
    Suzuki, Takuo
    Tada, Minoru
    Ishii-Watabe, Akiko
    BIOLOGICALS, 2020, 63 : 39 - 47
  • [3] MONITORING OF TNF-ALPHA BLOCKERS INFLIXIMAB AND ADALIMUMAB BY MEASURING TROUGH LEVEL CONCENTRATIONS AND ANTI-DRUG ANTIBODIES
    Westerlund, Johanna
    Jokiranta, T. Sakari
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2012, 41 (04) : 325 - 325
  • [4] Routinely utilized in-house assays for infliximab, adalimumab and their anti-drug antibody levels
    Manca Ogrič
    Polona Žigon
    David Drobne
    Borut Štabuc
    Snezna Sodin-Semrl
    Saša Čučnik
    Sonja Praprotnik
    Immunologic Research, 2018, 66 : 726 - 736
  • [5] Routinely utilized in-house assays for infliximab, adalimumab and their anti-drug antibody levels
    Ogric, Manca
    Zigon, Polona
    Drobne, David
    Stabuc, Borut
    Sodin-Semrl, Snezna
    Cucnik, Sasa
    Praprotnik, Sonja
    IMMUNOLOGIC RESEARCH, 2018, 66 (06) : 726 - 736
  • [6] ANALYSIS OF REAL-LIFE INFLIXIMAB AND ADALIMUMAB DATA: DRUG SWITCHING AND FATE OF ANTIDRUG ANTIBODIES AND TROUGH LEVELS OVER TIME
    Hol, D.
    Valtanen, S.
    Havana, M.
    Kroger, L.
    Eklund, K.
    Jokiranta, T. S.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 600 - 600
  • [7] POSITIVITY THRESHOLDS OF TOTAL INFLIXIMAB AND ADALIMUMAB ANTI-DRUG ANTIBODY ASSAYS AND IMPACT IN CLINICAL PRACTICE
    Nice, Rachel
    Chanchlani, Neil
    Kennedy, Nicholas A.
    Green, Harry D.
    Lin, Simeng
    Gordon, Claire
    Chee, Desmond
    Hamilton, Benjamin
    Bewshea, Claire
    Goodhand, James
    Ahmad, Tariq
    McDonald, Timothy
    Perry, Mandy
    GUT, 2021, 70 : A103 - A103
  • [8] Predictors of sub-therapeutic infliximab or adalimumab trough levels and anti-drug antibodies and their influence on therapeutic decisions
    Goldberg, R.
    Beswick, L.
    Van Langenberg, D.
    Sally, B.
    Rosella, O.
    Gibson, P.
    Moore, G.
    JOURNAL OF CROHNS & COLITIS, 2014, 8 : S223 - S223
  • [9] Positivity thresholds of total infliximab and adalimumab anti-drug antibody assay: The prevalence of clearing and transient anti-drug antibodies in a national therapeutic drug monitoring service
    Nice, R.
    Chanchlani, N.
    Green, H.
    Bewshea, C.
    Kennedy, N.
    Ahmad, T.
    Goodhand, J.
    McDonald, T.
    Perry, M.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S018 - S019
  • [10] Evaluation of the Homogenous Mobility Shift Assay for Infliximab and Adalimumab Anti-drug Antibody Detection in the Clinical Laboratory
    Keating, Paula Elizabeth
    Hock, Barry D.
    Chin, Paul K. L.
    O'Donnell, John Liston
    Barclay, Murray Lindsay
    THERAPEUTIC DRUG MONITORING, 2024, 46 (05) : 619 - 626
1234